TrialClinical and translational science2021

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.

Martin Kaul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.